

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	1
SCOPE OF REPORT.....	1
INTENDED AUDIENCE.....	2
METHODOLOGY.....	2
INFORMATION SOURCES.....	2
ANALYST CREDENTIALS.....	2
RELATED BCC REPORTS.....	2
BCC ONLINE SERVICES.....	3
DISCLAIMER.....	3
CHAPTER TWO: SUMMARY.....	4
SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, THROUGH 2014 (\$ MILLIONS).....	4
SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, 2008-2014 (\$ MILLIONS).....	4
FORECAST SUMMARY.....	5
CHAPTER THREE OVERVIEW.....	6
DEFINITION AND MARKET STRUCTURE.....	6
WHAT IS ALZHEIMER'S DISEASE?.....	6
TABLE 1 U.S. ALZHEIMER'S PATIENTS, 2000–2050 (MILLIONS).....	6
FIGURE 1 U.S. ALZHEIMER'S PATIENTS, 2000–2050 (MILLIONS).....	7
Role of the Cholinergic System.....	7
Role of Beta-Amyloid Protein.....	8
Behavioral Manifestations of AD.....	9
INCIDENCE AND PREVALENCE.....	9
TABLE 2 POPULATION BY SELECTED GEOGRAPHIC REGION, 2009– 2050 (MILLIONS).....	9
TABLE 3 PERCENT POPULATION OVER 65, BY REGION (%).....	10
TABLE 4 PEOPLE WITH ALZHEIMER'S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS).....	10
FIGURE 2 PEOPLE WITH ALZHEIMER'S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS).....	10
TABLE 5 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET.....	11
FIGURE 3 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET (%).....	11
TABLE 6 GLOBAL DISEASE PREVALENCE: ALZHEIMER'S DISEASE (%).....	12
STAGES OF ALZHEIMER'S DISEASE.....	12
Stages of Alzheimer's ... (Continued).....	13
DIAGNOSIS.....	14
TABLE 7 DIAGNOSTIC TESTS.....	15

How Accurate are the Screening Tests? .....	16
KEY EVENTS .....	17
PATENT EXPIRATIONS.....	17
NEW PRODUCT LAUNCHES .....	18
PRICING .....	18
KEY MARKETS.....	18
TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, THROUGH 2014 (\$ MILLIONS) .....	18
FIGURE 4 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2008-2014 (\$ MILLIONS).....	19
MARKET SIZE AND KEY PLAYERS .....	19
THERAPEUTICS .....	20
TABLE 9 EXISTING TREATMENTS: ALZHEIMER'S DISEASE.....	20
TABLE 10 GLOBAL EXISTING MARKET FOR SYMPTOM- ADDRESSING ALZHEIMER'S DISEASE, BY TYPE, 2002-2009 (\$ MILLIONS).....	20
TABLE 10 (CONTINUED).....	21
TABLE 11 GLOBAL MARKET FOR ALZHEIMER'S DRUG CLASSES BY GEOGRAPHICAL REGION (U.S., EUROPE, JAPAN), 2009 ESTIMATED (\$ MILLIONS) .....	21
TABLE 12 TYPES OF DRUGS USED TO TREAT ALZHEIMER'S DISEASE.....	21
TABLE 13 MARKET SHARE OF EXISTING THERAPEUTICS FOR ALZHEIMER'S DISEASE, 2008.....	22
TABLE 14 BREAKDOWN OF TREATMENT MARKET BY DISEASE SEVERITY (%).....	22
TABLE 15 DEMENTIA RATE BY UNDERLYING DISEASE STATE (%) .....	23
TABLE 16 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%) .....	23
TABLE 17 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, THROUGH 2014 (\$ MILLIONS).....	24
FIGURE 5 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, 2007- 2014 (\$ MILLIONS).....	24
TABLE 18 GLOBAL POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS, THROUGH 2014 (\$ MILLIONS).....	24
TABLE 18 (CONTINUED).....	25
FIGURE 6 GLOBAL MEMORY/COGNITION THERAPEUTICS MARKET BY DISEASE AREA, 2008 (%).....	25
Key Players .....	26
TABLE 19 MARKET SHARE OF TOP COMPANIES WORKING IN MEMORY AND COGNITION (%).....	26
TABLE 20 MARKETED TREATMENTS: ALZHEIMER'S DISEASE.....	26
TABLE 20 (CONTINUED).....	27

Drivers.....	27
Issues and Challenges .....	27
IMAGING AND DIAGNOSTICS .....	27
Current Use in Alzheimer’s Disease.....	27
Current Use in ... (Continued) .....	28
Diagnostic Testing Segments.....	29
Imaging .....	29
<i>TABLE 21 IMAGING MARKET, 2008 (\$ MILLIONS)</i> .....	30
<i>FIGURE 7 IMAGING MARKET, 2008 (\$ MILLIONS)</i> .....	30
Standardization Needed.....	30
Diagnostics.....	31
Novel Imaging Agents .....	32
Opportunities for Biomarkers in AD .....	33
<i>TABLE 22 BIOMARKERS FOR ALZHEIMER’S DISEASE</i> .....	34
<i>TABLE 22 (CONTINUED)</i> .....	35
<i>TABLE 23 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL</i> <i>TRIALS, THROUGH 2014 (\$ MILLIONS)</i> .....	36
<i>FIGURE 8 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL</i> <i>TRIALS, 2008-2014 (\$ MILLIONS)</i> .....	36
Opportunities for ... (Continued) .....	37
Opportunities for ... (Continued) .....	38
<i>TABLE 24 U.S. CLINICAL TRIAL MARKET FOR BIOMARKERS BY</i> <i>PHASE—NUMBER OF TRIALS, PATIENTS, BIOMARKER</i> <i>PATIENTS, COST PER TEST, MARKET SIZE, 2008</i> .....	39
<i>TABLE 25 CLINICAL TRIAL MARKET FOR BIOMARKERS BY</i> <i>GEOGRAPHICAL REGION, 2008 (\$ MILLIONS)</i> .....	39
Testing Hypotheses .....	40
Diagnostic Tests.....	40
Diagnostic Tests (Continued) .....	41
Key Players .....	42
Agilent Technologies .....	42
Bioscan .....	42
Capintec Inc. ....	43
Digirad Corporation .....	43
Gamma Medica-Ideas .....	43
GE Healthcare .....	44
Hitachi Medical Systems America Inc. ....	44
Nymox.....	44
OptoSonics Inc. ....	45
Philips Healthcare .....	46
Positron Corp. ....	46
Siemens Healthcare .....	47
Spectrum Dynamics Ltd. ....	47
Toshiba Medical Systems .....	48

UltraSPECT Ltd .....	48
VisEn Medical Inc.....	48
Zecotek Imaging Systems .....	49
Drivers.....	49
Issues and Challenges .....	49
SWOT ANALYSIS.....	50
<i>TABLE 26 SWOT ANALYSIS OF EXISTING ALZHEIMER'S DISEASE</i>	
<i>MARKET AND PLAYERS.....</i>	<i>50</i>
CHAPTER FOUR: TECHNOLOGIES AND APPLICATIONS.....	51
COMMON MECHANISMS OF ACTION .....	51
CHOLINESTERASE INHIBITORS .....	52
<i>TABLE 27 CHOLINESTERASE INHIBITORS .....</i>	<i>52</i>
<i>TABLE 28 PRODUCT SIDE EFFECT COMPARISON (%).....</i>	<i>53</i>
<i>FIGURE 9 PRODUCT SIDE EFFECT COMPARISON (%) .....</i>	<i>53</i>
<i>TABLE 29 VACCINES.....</i>	<i>54</i>
<i>TABLE 30 ANTI-OXIDANTS.....</i>	<i>54</i>
NMDA ANTAGONISTS.....	54
<i>TABLE 31 NMDA ANTAGONISTS .....</i>	<i>55</i>
NICOTINICS.....	55
<i>TABLE 32 NICOTINIC ACETYLCHOLINE ANTAGONISTS.....</i>	<i>56</i>
CALCINEURINS .....	56
<i>TABLE 33 CALCINEURINS .....</i>	<i>56</i>
GABA MODULATORS .....	56
<i>TABLE 34 ANTI-EPILEPTIC/GABA MODULATORS .....</i>	<i>57</i>
HORMONES .....	57
<i>TABLE 35 HORMONES.....</i>	<i>58</i>
OTHER THERAPEUTIC MECHANISMS.....	58
<i>TABLE 36 OTC TREATMENTS/NATURAL PRODUCTS.....</i>	<i>59</i>
IMAGING AND DIAGNOSTICS—MODALITIES AND	
APPLICATIONS.....	59
IMAGING AND DIAGNOSTICS...(CONTINUED).....	60
NUCLEAR MEDICINE .....	61
Positron Emission Tomography (PET) .....	61
Single Photon Emission Computed Tomography (SPECT) .....	62
Gamma Cameras .....	63
CT (COMPUTED TOMOGRAPHY) .....	63
DEXA .....	63
MRI (MAGNETIC RESONANCE IMAGING) .....	64
ULTRASOUND .....	65
X-RAY .....	65
FUSION IMAGING.....	66
PET/CT.....	66
SPECT/CT.....	67
SPECT-CT in Cardiology.....	67

SPECT-CT in General Nuclear Medicine .....	68
SPECT-CT in Neurology .....	68
DIAGNOSTIC IMAGING IN ALZHEIMER'S .....	69
DISEASE-MODIFYING VS. TREATMENT OF SYMPTOMS .....	70
SYMPTOMATIC RELIEF—LIFE-CYCLE MANAGEMENT OF EXISTING PRODUCTS .....	71
OTHER DRUGS TARGETING SYMPTOMATIC RELIEF .....	71
DRUG RE-PURPOSING .....	72
GENERICS .....	72
CHAPTER FIVE: WORLDWIDE INDUSTRY STRUCTURE .....	73
GROWTH DRIVERS .....	73
AGING POPULATION .....	73
OFF-LABEL USE .....	74
UNDERSTANDING OF MECHANISMS .....	75
Transcranial Magnetic Stimulation .....	76
Genetic Modifications .....	76
GROWTH OBSTACLES .....	77
UNDERSTANDING OF MECHANISMS .....	77
<i>TABLE 37 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%)</i> .....	78
CO-MORBID DISEASE STATES .....	78
KEY COMPETITIVE FACTORS .....	78
PRODUCT LAUNCH .....	79
LIFE CYCLE MANAGEMENT .....	79
PAYORS .....	79
Payors (Continued) .....	80
INTERNATIONAL ASPECTS .....	81
<i>TABLE 38 PERCAPITA GOVERNMENT EXPENDITURE ON     HEALTHCARE BY COUNTRY, THROUGH 2006 (\$ MILLIONS)</i> .....	82
INTERNATIONAL ASPECTS (CONTINUED) .....	83
CHAPTER SIX: LEGISLATION AND REGULATORY ENVIRONMENT .....	84
VALIDATED TARGETS .....	84
LACK OF BIOMARKERS .....	84
TRANSLATIONAL MEDICINE .....	85
REIMBURSEMENT .....	86
CHAPTER SEVEN: RELATED DEALS AND PARTNERSHIPS .....	87
APPROACH .....	87
DIAGNOSTICS DEALS .....	88
OVERALL ACTIVITY .....	88
<i>TABLE 39 RELATED DEALS AND PARTNERSHIPS, 2004–2009</i> .....	89
<i>TABLE 39 (CONTINUED)</i> .....	90
<i>TABLE 39 (CONTINUED)</i> .....	91

CHAPTER EIGHT: PIPELINE.....	92
PIPELINE .....	92
<i>TABLE 40 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS, BY</i>	
<i>PHASE.....</i>	93
<i>TABLE 40 (CONTINUED).....</i>	94
<i>TABLE 40 (CONTINUED).....</i>	95
<i>TABLE 40 (CONTINUED).....</i>	96
<i>TABLE 40 (CONTINUED).....</i>	97
<i>TABLE 40 (CONTINUED).....</i>	98
<i>FIGURE 10 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS:</i>	
<i>NUMBER OF PROGRAMS AT EACH CLINICAL PHASE .....</i>	98
<i>FIGURE 10 (CONTINUED) .....</i>	99
 CHAPTER NINE: TRENDS AND CHALLENGES .....	 100
AWARENESS OF ALZHEIMER'S.....	100
DISEASE PATHWAYS BEING ELUCIDATED .....	100
MANY PROGRAMS IN DEVELOPMENT .....	101
<i>TABLE 41 SOME NOT-FOR-PROFIT ORGANIZATIONS AND</i>	
<i>CONSORTIA IN THE AD AREA.....</i>	101
MANY PROGRAMS IN DEVELOPMENT (CONTINUED).....	102
<i>TABLE 42 INVESTMENT IN ALZHEIMER'S DISEASE COMPANIES.....</i>	103
 CHAPTER TEN: OUTLOOK .....	 104
A VARIETY OF APPROACHES IN RESEARCH .....	104
MANY PROGRAMS IN DEVELOPMENT .....	105
 CHAPTER ELEVEN: PATENT ANALYSIS .....	 106
<i>TABLE 43 KEY PATENT EXPIRY—ALZHEIMER'S THERAPEUTICS,</i>	
<i>BY CATEGORY.....</i>	106
<i>TABLE 44 MAJOR U.S. PATENT HOLDERS/FILERS IN</i>	
<i>ALZHEIMER'S THERAPEUTICS AND TECHNOLOGIES.....</i>	107
<i>TABLE 45 PATENT APPLICATIONS (U.S.) .....</i>	107
<i>TABLE 45 (CONTINUED).....</i>	108
<i>TABLE 45 (CONTINUED).....</i>	109
<i>TABLE 45 (CONTINUED).....</i>	110
<i>TABLE 45 (CONTINUED).....</i>	111
<i>TABLE 45 (CONTINUED).....</i>	112
<i>TABLE 45 (CONTINUED).....</i>	113
<i>TABLE 45 (CONTINUED).....</i>	114
<i>TABLE 45 (CONTINUED).....</i>	115
<i>TABLE 45 (CONTINUED).....</i>	116
<i>TABLE 45 (CONTINUED).....</i>	117
<i>TABLE 45 (CONTINUED).....</i>	118
<i>TABLE 45 (CONTINUED).....</i>	119
<i>TABLE 45 (CONTINUED).....</i>	120

<i>TABLE 46 ISSUED PATENTS (U.S.)</i> .....	120
<i>TABLE 46 (CONTINUED)</i> .....	121
<i>TABLE 46 (CONTINUED)</i> .....	122
<i>TABLE 46 (CONTINUED)</i> .....	123
<i>TABLE 46 (CONTINUED)</i> .....	124
<i>TABLE 46 (CONTINUED)</i> .....	125
<i>TABLE 46 (CONTINUED)</i> .....	126
<i>TABLE 46 (CONTINUED)</i> .....	127
<i>TABLE 46 (CONTINUED)</i> .....	128
<i>TABLE 46 (CONTINUED)</i> .....	129
<i>TABLE 46 (CONTINUED)</i> .....	130
<i>TABLE 46 (CONTINUED)</i> .....	131

CHAPTER TWELVE: COMPANY PROFILES .....	132
ABLYNX.....	132
ACCERA, INC.....	132
ACUMEN PHARMACEUTICALS .....	133
AFFIRIS AG.....	133
AFFITECH AS .....	134
ALLON THERAPEUTICS (FKA NEURODISCOVERY).....	134
ALZHYME PTY.....	135
ASTELLAS.....	135
ASTRAZENECA.....	136
ATHENA DIAGNOSTICS (THERMO FISHER).....	136
AVERA PHARMACEUTICALS .....	137
BAXTER HEALTHCARE.....	137
BAYER SCHERING PHARMA.....	138
BELLUS HEALTH .....	138
BIOFUTURA.....	139
BIOMERIEUX.....	139
BIOVAIL.....	140
BOEHRINGER INGELHEIM .....	140
BRACCO.....	140
BRAINCELLS, INC. ....	140
BRISTOL MYERS SQUIBB .....	141
CELLZOME.....	141
CEREGENE .....	142
COGNITION PHARMACEUTICALS LLC.....	142
COGNITION THERAPEUTICS.....	142
COLUCID PHARMACEUTICALS.....	143
COMENTIS .....	143
CORTEX PHARMACEUTICALS.....	144
C2N DIAGNOSTICS.....	144
CYTOS BIOTECHNOLOGY .....	145
DAIICHI SANKYO .....	145

DEBIOPHARM .....	146
DURECT .....	146
EISAI .....	146
ELAN .....	147
ELI LILLY .....	147
ENVIVO PHARMACEUTICALS .....	148
ESTEVE .....	148
EVOTEC .....	149
EXONHIT THERAPEUTICS .....	149
FOREST LABORATORIES .....	150
GALANTOS PHARMA .....	150
GALENEA .....	151
GE HEALTHCARE .....	151
GLAXOSMITH KLINE .....	152
HELICON THERAPEUTICS .....	152
INTELLECT NEUROSCIENCES .....	153
INTRA-CELLULAR THERAPIES .....	153
INVERNESS MEDICAL INNOVATIONS .....	154
IPSEN .....	154
JOHNSON & JOHNSON .....	155
KEYNEUROTEK .....	155
LEXICON PHARMACEUTICALS .....	155
LINK MEDICINE .....	156
LUNDBECK .....	156
MEDIVATION .....	157
MEMORY PHARMACEUTICALS .....	157
MERCK .....	158
MERCKSERONO .....	158
MERZ PHARMA .....	158
MITHRIDION .....	159
MITSUBISHI TANABE .....	159
MORPHOSYS .....	160
MP BIOMEDICALS .....	161
NEUREN PHARMACEUTICALS .....	161
NEUROPTIX .....	162
NEUROSEARCH .....	163
NEURO-HITECH .....	163
NEWRON PHARMACEUTICALS .....	163
NOSCIRA SA .....	164
NOVARTIS .....	165
NYMOX .....	165
OLIGOMERIX .....	166
ORTHO-MCNEIL NEUROLOGICS .....	166
PFIZER .....	166



POWER3 MEDICAL PRODUCTS .....	167
PRANA BIOTECHNOLOGY .....	167
PROTEOTECH INC. ....	168
PSYCHOGENICS .....	168
ROCHE .....	168
SAMARITAN PHARMACEUTICALS.....	169
SANOFI-AVENTIS .....	170
SATORI PHARMACEUTICALS .....	170
SATORIS .....	170
SCIELE PHARMA .....	171
SIEMENS MEDICAL SOLUTIONS .....	171
SOLVAY .....	172
SUVEN LIFE SCIENCE .....	172
TAKEDA.....	173
TARGACEPT.....	173
TAURX THERAPEUTICS.....	173
TAUTATIS .....	174
TEIKOKU.....	175
TEVA PHARMACEUTICALS .....	175
TRANSTECH PHARMA.....	175
VOYAGER PHARMACEUTICAL / DURAMED.....	176
WATSON PHARMACEUTICALS.....	176
WYETH/PFIZER.....	177